TCGA-86-8358-01A-11R-2326-07
— · cohortA3
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA3
- subtype
- cohortA3
- age_years
- 44
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.610
- G2M_CHECKPOINT+0.580
- SPERMATOGENESIS+0.380
- MITOTIC_SPINDLE+0.370
- PANCREAS_BETA_CELLS+0.270
- HEDGEHOG_SIGNALING+0.210
- MYC_TARGETS_V1+0.130
- MTORC1_SIGNALING+0.060
- MYC_TARGETS_V2+0.060
- DNA_REPAIR+0.030
Top 10 suppressed
- APICAL_SURFACE-0.540
- INFLAMMATORY_RESPONSE-0.520
- TNFA_SIGNALING_VIA_NFKB-0.520
- COAGULATION-0.470
- CHOLESTEROL_HOMEOSTASIS-0.440
- INTERFERON_ALPHA_RESPONSE-0.430
- IL6_JAK_STAT3_SIGNALING-0.420
- ALLOGRAFT_REJECTION-0.400
- INTERFERON_GAMMA_RESPONSE-0.400
- TGF_BETA_SIGNALING-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-G2-A2EL-01A-12R-A18C-07 | — | — | 0.925 |
| 2 | TCGA-D8-A13Y-01A-11R-A115-07 | — | B | 0.922 |
| 3 | TCGA-C4-A0EZ-01A-21R-A24X-07 | — | — | 0.922 |
| 4 | BS_4PH1MBGR | medulloblastoma | — | 0.918 |
| 5 | BS_NKRYMHEP | medulloblastoma | — | 0.916 |
| 6 | BS_FCAKKZ20 | medulloblastoma | — | 0.916 |
| 7 | BS_7XQRH69M | medulloblastoma | — | 0.913 |
| 8 | BS_45J79YTF | high-grade glioma | — | 0.912 |
| 9 | BS_Y8D1F5WW | medulloblastoma | — | 0.912 |
| 10 | SRR13780269 | — | cohortSC | 0.910 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.610 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.580 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.380 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.370 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.270 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.210 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.130 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.060 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.060 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.030 | Idelalisib | — uncovered |